Clinical Report: Evaluating Cardiovascular Biomarkers for Assessing CCS Risk
Overview
This study investigates the role of cardiovascular biomarkers in identifying cerebral-cardiac syndrome (CCS) risk among acute ischemic stroke (AIS) patients. Key findings indicate that age, BNP, and Myo are significant independent risk factors for CCS.
Background
Cerebral-cardiac syndrome (CCS) is a serious complication following ischemic stroke, leading to increased morbidity and mortality. Early diagnosis of CCS is important. Despite its prevalence, the mechanisms and risk factors associated with CCS remain poorly understood.
Data Highlights
Biomarker
CCS Group (n=97)
Non-CCS Group (n=80)
p-value
BNP
Elevated
Normal
< 0.001
DD
Elevated
Normal
< 0.001
cTnI
Elevated
Normal
< 0.001
Myo
Elevated
Normal
< 0.001
CK-MB
Elevated
Normal
< 0.001
Key Findings
CCS occurred in 54.8% of the studied AIS patients.
BNP, DD, cTnI, Myo, and CK-MB levels were significantly higher in the CCS group compared to the non-CCS group.
Age, BNP, and Myo were identified as independent risk factors for CCS after adjusting for covariates.
The combined model of age, BNP, and Myo demonstrated an AUC of 0.945.
CCS significantly increases the risk of mortality in stroke patients, with a 2.7 times higher probability of death compared to non-CCS patients.
Clinical Implications
The identification of age, BNP, and Myo as risk factors for CCS can aid clinicians in early diagnosis and risk stratification of AIS patients.
Conclusion
The study highlights the importance of cardiovascular biomarkers in the early identification of CCS in AIS patients.
